# Bay City Capital's Biotech Investments: 16 Startups in Its Portfolio (2026) > The 16 Biotech startups Bay City Capital has backed, by stage: $1.3B raised between them. From the rounds we track; updated nightly. Source: https://millionrounds.com/portfolio-maps/bay-city-capital-biotech-portfolio (Millionrounds; every figure on the page links to its filing or article) ## Stage not reported 6 - [Epizyme](https://millionrounds.com/company/epizyme) - [*C* Cydan](https://millionrounds.com/company/cydan) - [*TB* Twist Biosciences](https://millionrounds.com/company/twist-biosciences) - [*VP* VIA Pharmaceuticals](https://millionrounds.com/company/via-pharmaceuticals) - [Aciex Therapeutics](https://millionrounds.com/company/aciex-therapeutics) - [Vivaldi Biosciences](https://millionrounds.com/company/vivaldi-biosciences) ## Series C and later 6 - [*D* Dermira](https://millionrounds.com/company/dermira) - [Civitas Therapeutics](https://millionrounds.com/company/civitas-therapeutics) - [*RP* Reliant Pharmaceuticals](https://millionrounds.com/company/reliant-pharmaceuticals) - [Presidio Pharmaceuticals](https://millionrounds.com/company/presidio-pharmaceuticals) - [Nabsys](https://millionrounds.com/company/nabsys) - [*MT* Menlo Therapeutics](https://millionrounds.com/company/menlo-therapeutics) ## Series B 2 - [*O* Oculis](https://millionrounds.com/company/oculis) - [Omicia](https://millionrounds.com/company/omicia) ## Series A 2 - [*V* Vtesse](https://millionrounds.com/company/vtesse) - [Syrrx](https://millionrounds.com/company/syrrx) ## Segment by segment ### Stage not reported 6 startups · $478M raised - [**Epizyme**](https://millionrounds.com/company/epizyme) Epizyme is a biopharmaceutical company focusing on treatments for blood cancer and tumors. United States $332M - [*C* **Cydan**](https://millionrounds.com/company/cydan) United States $60M - [*TB* **Twist Biosciences**](https://millionrounds.com/company/twist-biosciences) United States $60M - [*VP* **VIA Pharmaceuticals**](https://millionrounds.com/company/via-pharmaceuticals) VIA Pharmaceuticals is a biotechnology company focused on the development of small-molecule drugs to treat cardiovascular diseases. - $13M - [**Aciex Therapeutics**](https://millionrounds.com/company/aciex-therapeutics) Aciex is a biotech company developing products to fill unmet needs for ophthalmic therapeutics in order to build an ophthalmic franchise. United States $9.6M - [**Vivaldi Biosciences**](https://millionrounds.com/company/vivaldi-biosciences) Vivaldi Biosciences is a biotechnology company focused on developing intranasal, genetically engineered vaccines for viral respira United States $4.0M ### Series C and later 6 startups · $670M raised - [*D* **Dermira**](https://millionrounds.com/company/dermira) Dermira is a development-stage biotech company focused on developing and commercializing innovative new therapies in dermatology. United States $169M - [**Civitas Therapeutics**](https://millionrounds.com/company/civitas-therapeutics) Civitas develops pulmonary delivery therapies. United States $122M - [*RP* **Reliant Pharmaceuticals**](https://millionrounds.com/company/reliant-pharmaceuticals) Reliant Pharmaceuticals provides cardiovascular pharmaceutical products. - $115M - [**Presidio Pharmaceuticals**](https://millionrounds.com/company/presidio-pharmaceuticals) Presidio Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery of small-molecule antiviral therapeutics. United States $109M - [**Nabsys**](https://millionrounds.com/company/nabsys) Nabsys is a life sciences company focused on the development of solid-state, single-molecule positional sequencing technology. United States $105M - [*MT* **Menlo Therapeutics**](https://millionrounds.com/company/menlo-therapeutics) United States $50M ### Series B 2 startups · $65M raised - [*O* **Oculis**](https://millionrounds.com/company/oculis) Switzerland $36M - [**Omicia**](https://millionrounds.com/company/omicia) Global healthcare platform for genomics-driven precision medicine. United States $30M ### Series A 2 startups · $47M raised - [*V* **Vtesse**](https://millionrounds.com/company/vtesse) United States $42M - [**Syrrx**](https://millionrounds.com/company/syrrx) Syrrx, Inc. Canada $5.1M **How this map is made.** Every startup here works in Biotech and has raised money in a round we track that names Bay City Capital as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026. ## More portfolio maps [All portfolios](https://millionrounds.com/portfolio-maps) [Sector portfolio **Techstars' AI portfolio** 336 startups · $4.9B](https://millionrounds.com/portfolio-maps/techstars-ai-portfolio)[Sector portfolio **Alumni Ventures' AI portfolio** 302 startups · $36B](https://millionrounds.com/portfolio-maps/us-strategic-tech-fund-an-alumni-ventures-fund-ai-portfolio)[Sector portfolio **Andreessen Horowitz's AI portfolio** 259 startups · $426B](https://millionrounds.com/portfolio-maps/andreessen-horowitz-ai-portfolio)[Sector portfolio **General Catalyst's AI portfolio** 226 startups · $179B](https://millionrounds.com/portfolio-maps/general-catalyst-ai-portfolio)[Sector portfolio **Sequoia Capital's AI portfolio** 209 startups · $543B](https://millionrounds.com/portfolio-maps/sequoia-capital-ai-portfolio)[Sector portfolio **Khosla Ventures' AI portfolio** 176 startups · $251B](https://millionrounds.com/portfolio-maps/khosla-ventures-ai-portfolio) ## Raising from investors like Bay City Capital? Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports. [Find investors](https://millionrounds.com/login?join=1&next=/app/investors)[Market maps](https://millionrounds.com/market-maps)